Interleukin 6 targeting in refractory Takayasu arteritis: Serial noninvasive imaging is mandatory to monitor efficacy

Journal of Rheumatology

Volumn 40, Issue 12, 2013, Pages 1941-1944

  Youngstein, Taryn ^a   Mason, Justin C ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; TOCILIZUMAB;

AORTA ARCH SYNDROME; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; DRUG TARGETING; ECHOGRAPHY; HUMAN; IMAGE ANALYSIS; MAGNETIC RESONANCE ANGIOGRAPHY; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; INTERLEUKIN-6; TAKAYASU ARTERITIS;

EID: 84889059519     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.131232     Document Type: Review

References (20)

1. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009;68:318-23.
2. Mason JC. Takayasu arteritis - advances in diagnosis and management. Nat Rev Rheumatol 2010;6:406-15.
3. Ohigashi H, Haraguchi G, Konishi M, Tezuka D, Kamiishi T, Ishihara T, et al. Improved prognosis of Takayasu arteritis over the past decade - comprehensive analysis of 106 patients. Circ J 2012;76:1004-11.
4. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med 1994;120:919-29.
5. Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol 2005;17:16-24.
6. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004;50:2296-304.
7. Comarmond C, Plaisier E, Dahan K, Mirault T, Emmerich J, Amoura Z, et al. Anti TNF-α in refractory Takayasu's arteritis: Cases series and review of the literature. Autoimmun Rev 2012;11:678-84.
8. Youngstein T, Peters JE, Hamdulay SS, Mewar D, Price-Forbes A, Lloyd M, et al. Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF-α and IL-6 receptor targeted therapies in refractory Takayasu arteritis. Clin Exp Rheumatol 2013 Sep 30 [Epub ahead of print].
9. Noris M, Daina E, Gamba S, Bonazzola S, Remuzzi G. Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation 1999;100:55-60.
10. Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology 2006;45:545-8.
11. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006;2:619-26.
12. Hoyer BF, Mumtaz IM, Loddenkemper K, Bruns A, Sengler C, Hermann KG, et al. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 2012;71:75-9.
13. Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2008; 58:1197-2000.
14. Abisror N, Mekinian A, Lavigne C, Vandenhende MA, Soussan M, Fain O. Tocilizumab in refractory Takayasu arteritis: A case series and updated literature review. Autoimmun Rev 2013;12:1143-9.
15. Tombetti E, Franchini S, Papa M, Sabbadini MG, Baldissera E. Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center. J Rheumatol 2013;40:2047-51.
16. Misra R, Danda D, Rajappa SM, Ghosh A, Gupta R, Mahendranath KM, et al. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology 2013;52:1795-801.
17. Bredemeier M, Rocha CM, Barbosa MV, Pitrez EH. One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab. Clin Exp Rheumatol 2012;30:S98-100.
18. Xenitidis T, Horger M, Zeh G, Kanz L, Henes JC. Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis. Rheumatology 2013;52:1729-31.
19. Hernandez-Rodriguez J, Segarra M, Vilardell C, Sanchez M, Garcia-Martinez A, Esteban MJ, et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003;107:2428-34.
20. Pugliese F, Gaemperli O, Kinderlerer AR, Lamare F, Rimoldi OE, Mason JC, et al. Imaging of vascular inflammation with [11C]-PK11195 and PET/CT angiography. J Am Coll Cardiol 2010;56:33-9.